X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (52) 52
humans (45) 45
cancer (31) 31
chemotherapy (31) 31
female (27) 27
colorectal cancer (26) 26
male (26) 26
middle aged (26) 26
aged (24) 24
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
oxaliplatin (20) 20
cetuximab (19) 19
colorectal neoplasms - drug therapy (18) 18
1st-line treatment (17) 17
adult (17) 17
treatment outcome (17) 17
survival (16) 16
hematology, oncology and palliative medicine (15) 15
leucovorin (15) 15
metastasis (15) 15
aged, 80 and over (14) 14
care and treatment (14) 14
research (13) 13
camptothecin - analogs & derivatives (12) 12
fluorouracil - administration & dosage (12) 12
mutation (12) 12
colorectal neoplasms - pathology (11) 11
disease-free survival (11) 11
fluorouracil (11) 11
fluorouracil - therapeutic use (11) 11
surgery (11) 11
antineoplastic combined chemotherapy protocols - adverse effects (10) 10
drug therapy (10) 10
antibodies, monoclonal, humanized (9) 9
bevacizumab (9) 9
irinotecan (9) 9
leucovorin - administration & dosage (9) 9
leucovorin - therapeutic use (9) 9
organoplatinum compounds - therapeutic use (9) 9
antineoplastic agents - therapeutic use (8) 8
camptothecin - therapeutic use (8) 8
colorectal-cancer (8) 8
liver neoplasms - secondary (8) 8
metastases (8) 8
organoplatinum compounds - administration & dosage (8) 8
prognosis (8) 8
therapy (8) 8
adjuvant chemotherapy (7) 7
antineoplastic combined chemotherapy protocols - administration & dosage (7) 7
cancer research (7) 7
cancer therapies (7) 7
capecitabine (7) 7
digestive system diseases (7) 7
fluorouracil - adverse effects (7) 7
leucovorin - adverse effects (7) 7
life sciences (7) 7
liver metastases (7) 7
neoplasm staging (7) 7
chemotherapy, adjuvant (6) 6
colorectal neoplasms - genetics (6) 6
combination (6) 6
diagnosis (6) 6
metastatic colorectal cancer (6) 6
metastatic colorectal-cancer (6) 6
oncology, experimental (6) 6
radiotherapy (6) 6
survival analysis (6) 6
5-fluorouracil (5) 5
[ sdv.can ] life sciences [q-bio]/cancer (5) 5
adenocarcinoma (5) 5
adjuvant treatment (5) 5
camptothecin - adverse effects (5) 5
cancer patients (5) 5
carcinoma (5) 5
colon-cancer (5) 5
colonic neoplasms - genetics (5) 5
continuous-infusion (5) 5
cup (5) 5
further section · weitere sektionen (5) 5
immunohistochemistry (5) 5
kaplan-meier estimate (5) 5
kras (5) 5
liver neoplasms - drug therapy (5) 5
medicine & public health (5) 5
microsatellite instability (5) 5
neoadjuvant therapy (5) 5
neoplasm metastasis (5) 5
neoplasms (5) 5
open-label (5) 5
phase-iii (5) 5
proto-oncogene proteins b-raf - genetics (5) 5
resection (5) 5
review (5) 5
adenocarcinoma - drug therapy (4) 4
antibodies, monoclonal - administration & dosage (4) 4
antibodies, monoclonal - therapeutic use (4) 4
antimitotic agents (4) 4
antineoplastic agents (4) 4
camptothecin - administration & dosage (4) 4
carcinoma of unknown primary (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 1, pp. 38 - 47
Summary Background Neoadjuvant chemotherapy for unresectable colorectal liver metastases can downsize tumours for curative resection. We assessed the... 
Hematology, Oncology and Palliative Medicine | 1ST-LINE TREATMENT | LEUCOVORIN | PLUS IRINOTECAN | ONCOLOGY | BEVACIZUMAB | GUIDELINES | OXALIPLATIN | FLUOROURACIL | COMBINATION | HEPATIC RESECTION | CANCER | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Tomography, Spiral Computed | Liver Neoplasms - chemistry | Hepatectomy | Antibodies, Monoclonal, Humanized | Fluorouracil - therapeutic use | Austria | Leucovorin - adverse effects | Fluorouracil - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Female | Leucovorin - therapeutic use | Neoadjuvant Therapy | Retrospective Studies | Chemotherapy, Adjuvant | Cetuximab | Liver Neoplasms - secondary | Odds Ratio | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Camptothecin - therapeutic use | Liver Neoplasms - genetics | Risk Assessment | Liver Neoplasms - drug therapy | Linear Models | Liver Neoplasms - surgery | Proto-Oncogene Proteins - genetics | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Aged | Mutation | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Germany | Organoplatinum Compounds - adverse effects | Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 8, pp. 979 - 989
Journal Article
The lancet oncology, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 862 - 873
Summary Background Since the 1990s, fluorouracil-based adjuvant chemotherapy has significantly reduced the risk of tumour recurrence in patients with stage III... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | 1ST-LINE TREATMENT | THERAPY | ONCOLOGY | BEVACIZUMAB | ADJUVANT TREATMENT | NSABP C-07 | KRAS | COMBINATION | METASTATIC COLORECTAL-CANCER | CHEMOTHERAPY | ras Proteins - genetics | Colonic Neoplasms - genetics | Proto-Oncogene Proteins p21(ras) | Adenocarcinoma - pathology | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Diarrhea - chemically induced | Colonic Neoplasms - surgery | Fluorouracil - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Infusions, Intravenous - adverse effects | Adult | Female | Leucovorin - therapeutic use | Adenocarcinoma - genetics | Chemotherapy, Adjuvant | Cetuximab | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Exons - genetics | Proto-Oncogene Proteins - genetics | Adenocarcinoma - drug therapy | Mucositis - chemically induced | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colonic Neoplasms - pathology | Intention to Treat Analysis | Aged | Neoplasm Staging | Organoplatinum Compounds - therapeutic use | Organoplatinum Compounds - adverse effects | Adenocarcinoma - surgery | Prevention | Care and treatment | Chemotherapy | Colon cancer | Hospitals | Leucovorin | Product development | Cancer | Life Sciences
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2009, Volume 360, Issue 14, pp. 1408 - 1417
Journal Article
BMC Cancer, ISSN 1471-2407, 12/2011, Volume 11, Issue 1, pp. 509 - 509
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2008, Volume 26, Issue 9, pp. 1443 - 1451
Journal Article
DMW - Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 10/2013, Volume 138, Issue 41, pp. 2098 - 2103
Zusammenfassung Die Behandlung von Patienten mit kolorektalen Lebermetastasen hat sich durch die Möglichkeiten der Resektion und der zunehmend effektiveren... 
Übersicht | Review article | multidisciplinary therapy | colorectal cancer | chemotherapy | neoadjuvant therapy | liver metastases
Journal Article
Journal Article
British journal of cancer, ISSN 1532-1827, 2015, Volume 113, Issue 7, pp. 1027 - 1034
... Peuteman1,2, Carles Pericay5, Gunnar Folprecht6, John Zalcberg7, Chiara Zilocchi8,Emmanuelle Margherini9, Marielle Chiron10 and Eric Van Cutsem11 1Vesalius Research... 
anti-angiogenesis; aflibercept; metastatic colorectal cancer; predictive marker; KRAS mutation status; IL8 | aflibercept | ANGIOPOIETIN-2 | ANTITUMOR-ACTIVITY | IDENTIFICATION | CHEMOTHERAPY PLUS BEVACIZUMAB | BIOMARKERS | TRIAL | KRAS mutation status | IL8 | MODELS | ONCOLOGY | anti-angiogenesis | metastatic colorectal cancer | KRAS | predictive marker | BEVACIZUMAB-INDUCED HYPERTENSION | AGENT BEVACIZUMAB | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Recombinant Fusion Proteins - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Fluorouracil - therapeutic use | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Leucovorin - therapeutic use | Interleukin-8 - blood | Angiogenesis Inhibitors - adverse effects | Recombinant Fusion Proteins - administration & dosage | Colorectal Neoplasms - blood | Treatment Outcome | Receptors, Vascular Endothelial Growth Factor - administration & dosage | Biomarkers, Tumor - blood | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vascular Endothelial Growth Factor B - genetics | Aged | Biomarkers, Tumor - genetics | Polymorphism, Single Nucleotide | Mutation | Organoplatinum Compounds - therapeutic use | Receptors, Vascular Endothelial Growth Factor - adverse effects | Translational Therapeutics
Journal Article